$SXTC News
Last published 1mo ago
- 1mo agoSXTCChina SXT Pharmaceuticals, Inc. Announces Share ConsolidationPR NewswireTAIZHOU, China, Oct. 22, 2026 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) (the "Company"), today announced that it will effect a share consolidation of its Class A ordinary shares, no par value
- 1mo agoSXTCChina SXT Pharmaceuticals Inc Announces Termination of Additional Purchase RightPR NewswireTAIZHOU, China, Oct. 21, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ:SXTC) (the "Company"), today announced that it has entered into a termination letter agreement with the purchasers in its
- 1mo agoSXTCUnivest Securities, LLC Announces Closing of $12 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)GlobeNewswireNew York, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today
- 1mo agoSXTCChina SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct OfferingPR NewswireTAIZHOU, China, Oct. 8, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ:SXTC) (the "Company"), today announced that it has entered into a definitive agreement with certain institutional investors for
- 3mo agoSXTCChina SXT Pharmaceuticals, Inc. Announces Share ConsolidationGlobeNewswireTAIZHOU, China, Aug. 05, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) (the "Company"), today announced that it will effect a share consolidation of its Class A ordinary shares, no par
- 4mo agoSXTCUnivest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)GlobeNewswireNew York, July 24, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today
- 4mo agoSXTCChina SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct OfferingGlobeNewswireTAIZHOU, China, July 23, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals Inc. (NASDAQ:SXTC) (the "Company"), today announced that it has entered into a definitive securities purchase agreement with certain
- 8mo agoSXTCChina SXT Pharmaceuticals, Inc. Announces Share Re-classificationGlobeNewswireTAIZHOU, China, March 23, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (NASDAQ:SXTC) (the "Company" or "SXTC"), a specialty pharmaceutical company focusing on the research, development, manufacturing,
- 9mo agoSXTCChina SXT Pharmaceuticals, Inc. Announces Share ConsolidationGlobeNewswireTAIZHOU, China, Jan. 30, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (NASDAQ:SXTC) (the "Company" or "SXTC"), a specialty pharmaceutical company focusing on the research, development, manufacturing,
- 10mo agoSXTCCHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAINGlobeNewswireTAIZHOU, China, Jan. 15, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing,
- 10mo agoSXTCUnivest Securities, LLC Announces Closing of $10 Million Registered Direct Offering for its Client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)GlobeNewswireNew York, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the
- 10mo agoSXTCChina SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct OfferingGlobeNewswireTAIZHOU, China, Jan. 09, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals Inc. (NASDAQ:SXTC) (the "Company"), today announced that it has entered into a definitive agreement with a single investor for the purchase
- 10mo agoSXTCCHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC AI INSIGHTS INITIATIVE TO OPTIMIZE TRADITIONAL CHINESE MEDICINE PORTFOLIO, ENHANCE MARKET ANALYSIS AND EXPLORE AI-SUPPORTED CLINIC DEPLOYMENTGlobeNewswireTAIZHOU, China, Jan. 08, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development,
- 1y agoSXTCChina SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price DeficiencyGlobeNewswireTAIZHOU, China, March 17, 2025 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) (the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing,
- 1y agoSXTCChina SXT Pharmaceuticals, Inc. Announces Share ConsolidationGlobeNewswireTAIZHOU, China, Feb. 21, 2025 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (NASDAQ:SXTC) (the "Company" or "SXTC"), a specialty pharmaceutical company focusing on the research, development, manufacturing,
- 2y agoSXTCChina SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price DeficiencyGlobeNewswireJiangsu, China, , Oct. 07, 2024 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ:SXTC) announced today that on October 3, 2024, the Company received a notification letter from the
- 3y agoSXTCChina SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq's Minimum Bid Price RuleGlobeNewswireTAIZHOU, China, Oct. 26, 2023 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ:SXTC), a specialty pharmaceutical company focusing on the research, development,
- 3y agoSXTCChina SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock SplitGlobeNewswireTAIZHOU, China, Oct. 04, 2023 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ:SXTC), a specialty pharmaceutical company focusing on the research, development,
- 3y agoSXTCChina SXT Pharmaceuticals, Inc. Receives 180-day Extension from Nasdaq to Meet Minimum Bid Price RuleGlobeNewswireTAIZHOU, China, May 10, 2023 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ:SXTC), a specialty pharmaceutical company focusing on the research, development,
- 3y agoBONSXTCWSGBon Natural Life Limited Appoints Wallace Lee as New Chief Financial OfficerGlobeNewswireXIAN, China, April 25, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal
- 4y agoSXTCChina SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price DeficiencyGlobeNewswireJiangsu, China, Nov. 07, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ:SXTC) announced today that on November 3, 2022, the Company received a notification letter from the
- 4y agoSXTCChina SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share SplitGlobeNewswireTAIZHOU, China, May 18, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditio
- 4y agoSXTCChina SXT Pharmaceuticals, Inc. Enters into Securities Purchase Agreement to Issue a 6% Convertible Promissory Note in the Original Principal Amount of $2.8 MillionGlobeNewswireTAIZHOU, China, March 14, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ:SXTC), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional
- 4y agoSXTCAegis Capital Corp. Acted as Sole Bookrunner on a $4.1 Million Underwritten Public Offering of Ordinary Shares, Inclusive of the Over-Allotment, for China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC).ACCESS NewswireNEW YORK, NY / ACCESSWIRE / January 20, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on a $4.1 Million Underwritten Public Offering of Ordinary Shares, Inclusive of the Over-Allotment, for China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC). About Chin
- 4y agoSXTCChina SXT Pharmaceuticals, Inc. Announces Successful Closing of $4.1 Million Follow-on Underwritten Offering of Ordinary Shares and Pre-Funded Warrants With Simultaneous Exercise of the Over-AllotmentGlobeNewswireTAIZHOU, China, Jan. 20, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ:SXTC), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chi
- 4y agoSXTCChina SXT Pharmaceuticals, Inc. Prices $3.5 Million Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary SharesGlobeNewswireTAIZHOU, China, Jan. 18, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ:SXTC), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Ch
- 4y agoSXTCChina SXT Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary SharesGlobeNewswireTAIZHOU, China, Jan. 14, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ:SXTC), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chi
- 4y agoSXTCChina SXT Pharmaceuticals, Inc. Adds Newly Developed Kuihuapan and Zhudanfen Advanced TCMP Products, and Announces the Expected Continuous Growth of Its Production Capacity of LuxuejinPR NewswireTAIZHOU, China, Jan. 14, 2022 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional
- 4y agoCNVAXSPCESPPI+1Thinking about buying stock in China SXT Pharmaceuticals, Virgin Galactic, Citigroup, Novavax, or Spectrum Pharmaceuticals?PR NewswireNEW YORK, Jan. 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SXTC, SPCE, C, NVAX, and SPPI. To
- 4y agoSXTCChina SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price DeficiencyPR NewswireTAIZHOU, China, Dec. 16, 2021 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ:SXTC) announced today that on December 14, 2021, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of
- 5y agoSXTCChina SXT Pharmaceuticals, Inc. Obtained a New Pharmaceutical Manufacturing Permit and Passed Its GMP Compliance-InspectionPR NewswireTAIZHOU, China, Oct. 18, 2021 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Ch
- 5y agoSXTCChina SXT Pharmaceuticals, Inc. Announces 1 for 4 Reverse Share SplitPR NewswireChina SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research,...
- 5y agoSXTCChina SXT Pharmaceuticals, Inc. Enters into Non-Binding LOI to Acquire Jiangsu Renji Pharmaceutical Chain Co., Ltd.PR NewswireChina SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company") announced today that it has entered into a non-binding letter of intent ...
- 6y agoSXTCNASDAQ Granted China SXT Pharmaceuticals, Inc. 180-Day Extension to Regain Compliance with Bid Price RequirementPR NewswireChina SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research,...
- 6y agoSXTCChina SXT Pharmaceuticals, Inc. Announces That It Received a Grant Supported by City GovernmentPR NewswireChina SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research,...
- 6y agoSXTCChina SXT Pharmaceuticals, Inc. Announces Plans to Increase ProductionBusiness WireTAIZHOU, China--(BUSINESS WIRE)--China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), announced today that it will be increasing its production of its entire TCM product line, in response to recent Chinese governme ...
- 6y agoSXTCChina SXT Pharmaceuticals, Inc. Announced Regulatory Approval of Its DNA Exam LaboratoryPR NewswireChina SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research,...
- 6y agoSXTCChina SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price DeficiencyPR NewswireChina SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC) announced today that on December 27, 2019 the Company received a...
- 7y agoSXTCChina SXT Pharmaceuticals, Inc. Announces Filing of Annual Report on Form 20-F for Year Ended March 31, 2019PR NewswireChina SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research,...
- 7y agoSXTCChina SXT Pharmaceuticals, Inc. Receives New Pharmaceutical GMP CertificatePR NewswireChina SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research,...
- 7y agoSXTCChina SXT Pharmaceuticals, Inc. Announces TCM Homologous Supplements ProductionPR NewswireChina SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research,...